Minomic International Ltd. focuses on the development of immuno-oncology solutions for the diagnosis of cancer. I have been a part of several commercial projects with Minomic International Ltd. towards the development of novel prostate cancer diagnostics. Due to the contract nature of these projects, no more information other than the titles (see Outputs tab) of the projects and those involved can be disclosed.

Contracts were negotiated between Minomic International Inc. and the Centre for Advanced Imaging at the University of Queensland. I was involved with the radiolabelling, purification of the radiolabelled compounds, imaging, animal handling, and treatment monitoring. All people involved in this project (other than myself) and their roles are listed below (Affiliations denoted in superscripts).

  • Kristofer J. Thurecht1,2,3,4 – Project design and management
  • Nicholas L. Fletcher1,2,3 – Radiolabelling and purification.

Affiliations

  1. Centre for Advanced Imaging, The University of Queensland, St Lucia, QLD 4072, Australia.
  2. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia.
  3. ARC Centre of Excellence in Convergent BioNano Science and Technology, The University of Queensland, St Lucia, QLD 4072, Australia
  4. ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, St Lucia, QLD 4072, Australia

Publications & Presentations

Targeted beta therapy of prostate cancer with (177)Lu-labelled Miltuximab(R) antibody against glypican-1 (GPC-1)

Journal Article
Yeh, M. C. and Tse, B. W. C. and Fletcher, N. L. and Houston, Z. H. and Lund, M. and Volpert, M. and Stewart, C. and Sokolowski, K. A. and Jeet, V. and Thurecht, K. J. and Campbell, D. H. and Walsh, B. J. and Nelson, C. C. and Russell, P. J.
EJNMMI Res 10, 46 (2020).
Publication year: 2020